达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301126 达嘉维康

已收盘 03-30 15:00:00

{"stockData":{"symbol":"301126","market":"SZ","secType":"STK","nameCN":"达嘉维康","latestPrice":11.38,"timestamp":1774854192000,"preClose":11.35,"halted":0,"volume":3080009,"delay":0,"changeRate":0.0026,"floatShares":138000000,"shares":204999999,"eps":-0.0233,"marketStatus":"已收盘","change":0.03,"latestTime":"03-30 15:00:00","open":11.2,"high":11.45,"low":11.15,"amount":34845700,"amplitude":0.0264,"askPrice":11.39,"askSize":24,"bidPrice":11.38,"bidSize":520,"shortable":0,"etf":0,"ttmEps":-0.0233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774920600000},"marketStatusCode":5,"adr":0,"adjPreClose":11.35,"symbolType":"stock","openAndCloseTimeList":[[1774834200000,1774841400000],[1774846800000,1774854000000]],"highLimit":12.49,"lowLimit":10.22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":205403200,"isCdr":false,"pbRate":1.34,"roa":"--","roe":"0.29%","epsLYR":0.13,"committee":0.58368,"marketValue":2337000000,"turnoverRate":0.0223,"status":0,"floatMarketCap":1569000000},"requestUrl":"/m/hq/s/301126","defaultTab":"news","newsList":[{"id":"2622738238","title":"达嘉维康（301126）披露对外担保进展公告，3月27日股价上涨3.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622738238","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622738238?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:39","pubTimestamp":1774622357,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，达嘉维康报收于11.35元，较前一交易日上涨3.18%，最新总市值为23.31亿元。该股当日开盘10.94元，最高11.35元，最低10.76元，成交额达4488.47万元，换手率为2.91%。近日，湖南达嘉维康医药产业股份有限公司发布《关于对外担保的进展公告》。上述担保在公司2025年度股东大会审议通过的30亿元担保额度范围内。截至公告日，公司累计担保余额为152,755.91万元，占最近一期经审计净资产的86.95%，均为对合并报表范围内子公司的担保，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700050435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2620198732","title":"达嘉维康（301126）披露对外担保进展公告，3月20日股价下跌3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620198732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620198732?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:33","pubTimestamp":1774017196,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，达嘉维康报收于11.25元，较前一交易日下跌3.68%，最新总市值为23.11亿元。湖南达嘉维康医药产业股份有限公司于2026年3月20日发布公告，公司与中国光大银行股份有限公司长沙新华支行签订《最高额保证合同》，为全资子公司达嘉维康生物制药有限公司提供总额1,000万元的连带责任保证担保。截至公告日，公司对达嘉生物累计提供担保余额为4,336.00万元，占公司最近一期经审计净资产的2.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2618130421","title":"达嘉维康（301126）披露对外担保进展公告，3月12日股价下跌1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618130421?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:46","pubTimestamp":1773326775,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，达嘉维康报收于12.1元，较前一交易日下跌1.71%，最新总市值为24.85亿元。该股当日开盘12.37元，最高12.39元，最低12.06元，成交额达3925.12万元，换手率为2.34%。公司于2026年3月12日发布《关于对外担保的进展公告》。截至公告日，公司对子公司的担保额度合计30亿元，累计担保余额151,604.70万元，占公司最近一期经审计净资产的86.30%。公司不存在对合并报表外单位担保、逾期担保及诉讼担保事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200039123.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2609560518","title":"达嘉维康最新公告：实控人之一致行动人拟减持公司不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2609560518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609560518?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:40","pubTimestamp":1770378048,"startTime":"0","endTime":"0","summary":"达嘉维康(301126.SZ)公告称，公司控股股东、实控人之一致行动人长沙同嘉投资管理合伙企业（有限合伙）计划15个交易日后的3个月内，以集中竞价和大宗交易方式，减持公司股份不超过616.21万股（占公司总股本的3%）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600036069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"1146187545","title":"达嘉维康股东拟减持不超过3%股份 减持窗口期为3月10日至6月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=1146187545","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146187545?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:31","pubTimestamp":1770377485,"startTime":"0","endTime":"0","summary":"达嘉维康（301126）发布公告称，公司持股5%以上股东计划通过集中竞价或大宗交易方式，在2024年3月10日至6月9日期间减持公司股份不超过总股本的3%。此次减持计划将根据市场情况、公司股价等因素择机实施。减持股东将严格遵守相关法律法规关于减持比例、信息披露等要求。若减持计划实施完毕，该股东持股比例将相应下降，但不会导致公司控制权发生变更。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2606217675","title":"达嘉维康(301126.SZ)发预亏，预计2025年度归母净亏损2.5亿元至3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217675","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606217675?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:10","pubTimestamp":1769429430,"startTime":"0","endTime":"0","summary":"智通财经APP讯，达嘉维康(301126.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净亏损2.5亿元至3亿元;扣除非经常性损益后的净亏损2.5亿元至3亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"达嘉维康(301126.SZ)发预亏，预计2025年度归母净亏损2.5亿元至3亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2606917217","title":"达嘉维康：预计2025年全年营业收入55亿元至60亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606917217","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606917217?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:02","pubTimestamp":1769428975,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康发布业绩预告，预计2025年全年营业收入55亿元至60亿元。达嘉维康2025年三季报显示，前三季度公司主营收入41.3亿元，同比上升3.69%；归母净利润509.74万元，同比下降86.02%；扣非净利润388.18万元，同比下降89.02%；其中2025年第三季度，公司单季度主营收入14.22亿元，同比上升2.79%；单季度归母净利润420.38万元，同比下降8.94%；单季度扣非净利润460.61万元，同比上升8.87%；负债率72.68%，投资收益16.03万元，财务费用8065.47万元，毛利率17.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600031141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126"],"gpt_icon":0},{"id":"2605416927","title":"股市必读：达嘉维康（301126）1月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605416927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605416927?lang=zh_cn&edition=full","pubTime":"2026-01-23 01:30","pubTimestamp":1769103027,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，达嘉维康报收于13.92元，上涨3.11%，换手率11.46%，成交量15.8万手，成交额2.19亿元。董秘最新回复投资者： 请问贵公司截止到一月二十日股东人数是多少？当日关注点来自交易信息汇总：1月22日主力资金净流入1515.96万元，显示主力对个股关注度提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300000781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2605174990","title":"达嘉维康：统一股东人数信息披露口径","url":"https://stock-news.laohu8.com/highlight/detail?id=2605174990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605174990?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:36","pubTimestamp":1768984573,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康01月21日在投资者关系平台上答复投资者关心的问题。随着监管机构对信息披露公平性要求不断提升，为确保所有投资者均通过法定渠道同步、公平地获取信息，公司经审慎评估后，统一了此类信息的披露口径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100026057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2603819936","title":"达嘉维康：积极推进AI技术促进业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603819936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603819936?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:53","pubTimestamp":1768308790,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司是否有采用相关AI技术或布局AI应用达嘉维康回复：您好，公司密切关注AI人工智能在医疗领域的应用，积极研究论证新业态与公司现有业务发展的契合度，积极推进落地前沿AI人工智能等创新技术促进公司业务高质量发展。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300039861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2601284417","title":"达嘉维康：公司截至2025年12月31日股东人数为16,103人","url":"https://stock-news.laohu8.com/highlight/detail?id=2601284417","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601284417?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:48","pubTimestamp":1767746891,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月31日的股东人数是多少？谢谢达嘉维康回复：您好，公司截至 2025年12月31日股东人数为16,103人。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700005012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2600062773","title":"每周股票复盘：达嘉维康（301126）募投项目节余251.99万元补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2600062773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600062773?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:21","pubTimestamp":1767378070,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，达嘉维康报收于12.29元，较上周的13.36元下跌8.01%。本周，达嘉维康12月29日盘中最高价报13.5元。12月30日盘中最低价报11.85元。达嘉维康当前最新总市值25.24亿元，在医药商业板块市值排名32/32，在两市A股市值排名4848/5181。公司公告汇总湖南达嘉维康医药产业股份有限公司首次公开发行股票募投项目已结项，截至2025年12月29日，节余募集资金251.99万元将永久补充流动资金。本次节余金额低于募集资金净额的5%，免于履行董事会审议程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2595789863","title":"达嘉维康（301126）披露对外担保进展公告，12月29日股价下跌4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789863?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:52","pubTimestamp":1767001956,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，达嘉维康报收于12.74元，较前一交易日下跌4.64%，最新总市值为26.17亿元。该股当日开盘13.5元，最高13.5元，最低12.49元，成交额达1.96亿元，换手率为11.14%。上述担保事项在公司2025年度预计担保额度30亿元范围内。截至公告日，公司累计担保余额149,604.45万元，占最近一期经审计净资产的85.16%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2591860994","title":"达嘉维康：旗下药店销售水银体温计","url":"https://stock-news.laohu8.com/highlight/detail?id=2591860994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591860994?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:24","pubTimestamp":1765869868,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)12月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！公司或子公司有没有生产或销售“水银体温计”？达嘉维康回复：您好，公司旗下各零售药店均有水银体温计、医用电子体温计等体温类监测产品的销售，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600019776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2590571486","title":"达嘉维康：截至2025年12月10日股东人数为15,994人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571486?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:48","pubTimestamp":1765529291,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)12月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止 2025 年 12 月 10 日股东人数是多少？谢谢！达嘉维康回复：您好，公司截至 2025年12月10日股东人数为15,994人。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200024557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2588403587","title":"达嘉维康：截至2025年11月28日股东人数为16,391人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588403587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588403587?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:39","pubTimestamp":1764664746,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康(301126)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日公司的股东人数是多少？谢谢达嘉维康回复：您好，公司截至 2025年11月28日股东人数为16,391人。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200022475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2586433102","title":"达嘉维康：磷酸奥司他韦颗粒已上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586433102","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586433102?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:51","pubTimestamp":1764233475,"startTime":"0","endTime":"0","summary":"证券之星消息，达嘉维康11月27日在投资者关系平台上答复投资者关心的问题。目前，公司子公司湖南天济草堂制药股份有限公司生产的磷酸奥司他韦颗粒已陆续在全国各大线下药店同步上市销售。此外，公司旗下各大零售药店均有退烧、止咳化痰等流感对症药品销售。针对季节性需求增长，公司已制定相应的生产计划，并能根据市场销售情况灵活调整产能，全力保障药品的安全稳定供应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700023512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2584873251","title":"达嘉维康最新公告：持股5%以上股东、董事钟雪松提前终止减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2584873251","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584873251?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:48","pubTimestamp":1763632122,"startTime":"0","endTime":"0","summary":"达嘉维康(301126.SZ)公告称，公司持股5%以上股东、董事钟雪松于2025年9月1日至11月20日期间，通过集中竞价交易方式累计减持公司股份2,050,700股，占公司总股本的1.00%。钟雪松决定提前终止本次股份减持计划，未完成减持的股份在剩余减持计划期间内将不再减持。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000027074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301126"],"gpt_icon":0},{"id":"2584123625","title":"达嘉维康：11月14日高管钟雪松减持股份合计10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584123625","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584123625?lang=zh_cn&edition=full","pubTime":"2025-11-17 21:04","pubTimestamp":1763384645,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月17日市场公开信息、上市公司公告及交易所披露数据整理，达嘉维康最新董监高及相关人员股份变动情况：2025年11月14日公司董事钟雪松共减持公司股份10.0万股，占公司总股本为0.0487%。达嘉维康近半年内的董监高及核心技术人员增减持详情如下：达嘉维康的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入535.65万，融资余额增加；融券净流出100.0，融券余额减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700034089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0},{"id":"2583490502","title":"达嘉维康（301126）披露召开2025年第四次临时股东会通知，11月14日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583490502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583490502?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:43","pubTimestamp":1763131398,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，达嘉维康报收于13.07元，较前一交易日上涨1.55%，最新总市值为26.85亿元。该股当日开盘12.82元，最高13.55元，最低12.74元，成交额达2.4亿元，换手率为13.17%。公司近日发布公告称，湖南达嘉维康医药产业股份有限公司将于2025年12月1日召开2025年第四次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为当日9:15至15:00。股权登记日为2025年11月25日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301126","BK0250"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774903727252,"stockEarnings":[{"period":"1week","weight":0.0921},{"period":"1month","weight":-0.1165},{"period":"3month","weight":-0.1306},{"period":"6month","weight":0.0002},{"period":"1year","weight":-0.0283},{"period":"ytd","weight":-0.074}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":-0.0576},{"period":"3month","weight":-0.0105},{"period":"6month","weight":0.0104},{"period":"1year","weight":0.1707},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南达嘉维康医药产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"16103人(较上一季度增加0.68%)","perCapita":"8562股","listingDate":"2021-12-07","address":"湖南省长沙市岳麓区茯苓路30号","registeredCapital":"20540万元","survey":"　　湖南达嘉维康医药产业股份有限公司的主营业务是药品、生物制品、医疗器械等产品的分销及零售业务。公司的主要产品是抗肿瘤药、免疫调节用药、心脑血管用药、呼吸系统用药、抗病毒用药、化学药制剂、中成药、生物制药、医疗器械、非药品、中药饮片、清热散结胶囊、脑得生丸、障眼明胶囊、舒筋活血胶囊、清热解毒类、心脑血管类、泌尿类。公司医药工业持续专注原创化学药、创新中药、首仿药、大健康产品的研究开发，是“湖南省重点实验室”“省级企业技术中心”“湖南省智能制造标杆车间”“国家级高新技术企业”。","listedPrice":12.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"达嘉维康,301126,达嘉维康股票,达嘉维康股票老虎,达嘉维康股票老虎国际,达嘉维康行情,达嘉维康股票行情,达嘉维康股价,达嘉维康股市,达嘉维康股票价格,达嘉维康股票交易,达嘉维康股票购买,达嘉维康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"达嘉维康(301126)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供达嘉维康(301126)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}